Mr. Eamonn Quinn:

That is why they were included in group one in our criticality assessment exercise. They were top of the pyramid and we engaged directly with the companies. We have identified the suppliers to the Irish market and hospitals. It involved going to the hospitals involved in the clinical space and understanding from where they were sourcing. It then involved going back to the suppliers to understand on several levels if they were committed to continuing supplying to the Irish market. Given that the United Kingdom is an island, the companies had to be asked if they had the materials to continue manufacturing the products. The assurances we received up to the first phase in April were positive. We repeated the exercise recently and the responses we received were extremely positive. There has been a high level of assurances in terms of commitment and the ability to supply the Irish market. There is a risk in moving the products from point A to point B. The companies have been asked to consider and are putting in place contingency measures also.